News

Atypical symptoms, odd lab findings delay CAD diagnosis

Atypical symptoms, including persistent blue discoloration and skin lesions in the extremities, along with uncommon laboratory findings, delayed a cold agglutinin disease (CAD) diagnosis for more than a decade in a 60-year-old woman, a study reports. “This case adds important context to the difficulty in diagnosis of this disease,”…

Physicians’ search for blood cancer reveals secondary CAD

A case of cold agglutinin disease (CAD) secondary to a type of blood cancer called B-cell lymphoma was confirmed after carefully examining blood samples under the microscope, a study reports. The case study illustrates the “importance of microscopic observation in the exploration of undergoing causes of cold agglutination,” the researchers…

Adenovirus triggered secondary CAD in toddler

For a toddler in Brazil, cold agglutinin disease (CAD) occurred secondary to an infection with an adenovirus, a common virus that can cause symptoms similar to a cold or the flu, a case study reports. According to the researchers, this represents “the first pediatric case of cold agglutinin syndrome…

Life quality gains with Enjaymo sustained for 2.5 years

Long-term treatment with Enjaymo (sutimlimab-jome) led to sustained improvements in life quality and reductions in fatigue for people with cold agglutinin disease (CAD), according to 2.5 years of data from the Phase 3 CARDINAL clinical trial. “[Enjaymo] provides sustained and durable treatment benefits in chronic CAD, including a…

Blood cancer treatments may help people with hard-to-treat CAD

Two approved blood cancer treatments, daratumumab and bortezomib, were each partially effective at reducing signs of cold agglutin disease (CAD) in two people with hard-to-treat cases of the autoimmune disorder, a study showed. These two therapies, alone or in combination, also were found to effectively treat five of six people with other…

Legionnaires’ disease ID’d as cause of secondary CAD

Legionnaires’ disease — a lung infection caused by a group of bacteria called Legionella — caused secondary cold agglutinin disease (CAD) in a 40-year-old man, a case study reports. The case, which represents the second reported case of CAD secondary to Legionnaires’ disease, suggest doctors should consider this infection…

Sanofi’s SAR445088 possible successor to Enjaymo

Sanofi’s experimental therapy SAR445088 effectively blocks the classic complement pathway — a part of the immune system that’s implicated in cold agglutinin disease (CAD) — and reduced red blood cell destruction in a cellular model of CAD, a study showed. SAR445088’s more targeted action may make it a…